Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)-Reference-Cited by-同舟云学术

Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)

Published:2021-12 Issue: Volume:159 Page:144-153
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Sakata Yoshihiko,Sakata Shinya,Oya Yuko^ORCID,Tamiya Motohiro,Suzuki Hidekazu,Shibaki Ryota,Okada Asuka,Kobe Hiroshi,Matsumoto Hirotaka^ORCID,Yokoi Takashi^ORCID,Sato Yuki,Uenami Takeshi,Saito Go,Tsukita Yoko,Inaba Megumi,Ikeda Hideki,Arai Daisuke^ORCID,Maruyama Hirotaka,Hara Satoshi,Tsumura Shinsuke^ORCID,Morinaga Jun,Sakagami Takuro^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference27 articles.

1. Screening for epidermal growth factor receptor mutations in lung cancer;Rosell;N Engl J Med,2009

2. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

3. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

4. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011

5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy;Medicine in Drug Discovery;2024-09

2. Intrinsic impacts of the expression of PD-L1 on postoperative recurrence in EGFR-mutated lung adenocarcinoma;Frontiers in Oncology;2024-08-30

3. It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC;Exploration of Targeted Anti-tumor Therapy;2024-07-19

4. Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study;Biomedicines;2024-06-25

5. Comparison of the efficacy of first‑/second‑generation EGFR‑tyrosine kinase inhibitors and osimertinib for EGFR‑mutant lung cancer with negative or low PD‑L1 expression;Molecular and Clinical Oncology;2024-05-01